The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era

Abstract

Allogeneic stem cell transplantation is an accepted standard therapy for chronic myeloid leukemia (CML). In recent years, however, the use of transplantation has diminished, largely because of the introduction of the novel tyrosine kinase inhibitor, imatinib mesylate. Despite the introduction of imatinib and the other new tyrosine kinase inhibitors, a rational role for transplantation remains. This review focuses on the indications for transplantation in the tyrosine kinase inhibitor era.